Post-traumatic stress disorder psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
103 registered studies are counted for post-traumatic stress disorder (PTSD). By compound: 24 psilocybin, 49 MDMA, 2 LSD, 2 DMT, 2 5-MeO-DMT, 1 ayahuasca, 29 ketamine and 2 ibogaine. By registry status: 25 recruiting, 8 not yet recruiting, 3 enrolling by invitation, 10 active, not recruiting, 35 completed, 4 terminated, 1 suspended, 8 withdrawn and 9 status not reported. By phase: 2 early phase 1, 15 phase 1, 62 phase 2, 9 phase 3, 1 phase 4, 4 not applicable and 10 not reported. Reported start years run from 2004 (earliest) to 2026 (latest).
Studies are matched when the title names post-traumatic stress disorder or PTSD. Titles that only mention trauma are not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 103 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 24 |
| MDMA | 49 |
| LSD | 2 |
| DMT | 2 |
| 5-MeO-DMT | 2 |
| Ayahuasca | 1 |
| Ketamine | 29 |
| Ibogaine | 2 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 25 | 24% |
| Not yet recruiting | 8 | 8% |
| Enrolling by invitation | 3 | 3% |
| Active, not recruiting | 10 | 10% |
| Completed | 35 | 34% |
| Terminated | 4 | 4% |
| Suspended | 1 | 1% |
| Withdrawn | 8 | 8% |
| Status not reported | 9 | 9% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 2 | 2% |
| Phase 1 | 15 | 15% |
| Phase 2 | 62 | 60% |
| Phase 3 | 9 | 9% |
| Phase 4 | 1 | 1% |
| Not applicable | 4 | 4% |
| Not reported | 10 | 10% |
Countries
Country is taken from the study's linked research site. 3 of 103 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 75 | 73% |
| Canada | 10 | 10% |
| Israel | 6 | 6% |
| Switzerland | 2 | 2% |
| Netherlands | 2 | 2% |
| Australia | 1 | 1% |
| Brazil | 1 | 1% |
| Czechia | 1 | 1% |
| United Kingdom | 1 | 1% |
| Pakistan | 1 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 47 |
| 2020 to 2023 | 28 |
| 2015 to 2019 | 14 |
| 2010 to 2014 | 9 |
| Before 2010 | 4 |
| Start date not reported | 1 |
Study design
- 93 interventional and 9 observational studies.
- Median planned or actual enrolment is 30 participants (range 3 to 376, across 94 records that report it).
Registered studies
The 50 studies with the latest start dates, newest first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin-Assisted Psychotherapy for Veterans With PTSD | NCT07792538 | Not yet recruiting | Phase 2 | 2026-12-01 | Psilocybin |
| MDMA-AT for PTSD in Young Adults With Childhood Trauma | NCT07765693 | Not yet recruiting | Phase 2 | 2026-10-31 | MDMA |
| Clinical Trial of MDMA-Assisted Therapy for Military Service Members With Posttraumatic Stress Disorder | NCT07704762 | Not yet recruiting | Phase 2 | 2026-10-01 | MDMA |
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder | NCT07570654 | Recruiting | Phase 2 | 2026-09-01 | Psilocybin |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07745569 | Not yet recruiting | Phase 2 | 2026-08-31 | Psilocybin |
| Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence | NCT06885996 | Not yet recruiting | Phase 2 | 2026-08-01 | Psilocybin |
| Intra-Sessional Autonomic Arc Detection in Ketamine-Assisted Therapy for PTSD: A Signal Characterisation Pilot Study | NCT07614581 | Not yet recruiting | Not reported | 2026-07-15 | Ketamine |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder | NCT07506395 | Recruiting | Phase 1 | 2026-05-01 | Psilocybin |
| MDMA Therapy in Veterans With PTSD | NCT07569159 | Recruiting | Phase 2 | 2026-05-01 | MDMA |
| MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder | NCT07118839 | Recruiting | Phase 2 | 2026-04-15 | MDMA |
| MDMA-Assisted Therapy for Stress Disorders in Healthcare Workers | NCT05455996 | Not yet recruiting | Phase 2 | 2026-04-01 | MDMA |
| KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury | NCT07563296 | Recruiting | Phase 2 | 2026-04-01 | Ketamine |
| Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | NCT07703722 | Recruiting | Phase 3 | 2026-04-01 | Psilocybin |
| Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) | NCT06378528 | Suspended | Early Phase 1 | 2026-03-01 | Ketamine |
| Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD | NCT06386003 | Active, not recruiting | Phase 2 | 2026-03-01 | Psilocybin |
| Psilocybin-Assisted Randomized Therapy | NCT07332143 | Recruiting | Phase 2 | 2026-03-01 | Psilocybin |
| MDMA-Assisted Massed Exposure Therapy for PTSD | NCT07288151 | Recruiting | Phase 2 | 2026-01-01 | MDMA |
| Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events | NCT07469098 | Recruiting | Phase 2 | 2025-12-24 | MDMA |
| Ayahuasca, Esketamine and PTSD | NCT07317206 | Recruiting | Phase 2 | 2025-12-20 | Ayahuasca, Ketamine |
| Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD | NCT06902974 | Recruiting | Phase 2 | 2025-12-01 | Psilocybin |
| Safety and Preliminary Efficacy of Organic Whole Psilocybin-Containing Mushrooms to Treat Patients Suffering From PTSD | NCT07275970 | Active, not recruiting | Phase 1 | 2025-12-01 | Psilocybin |
| Mindfulness-based Psilocybin Therapy for PTSD | NCT07104916 | Recruiting | Phase 2 | 2025-11-01 | Psilocybin |
| Ketamine Assisted Psychotherapy for Treating Comorbid Chronic Pain and PTSD | NCT07009158 | Recruiting | Phase 1 | 2025-10-01 | Ketamine |
| Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD) | NCT06989957 | Recruiting | Phase 1 | 2025-09-17 | Psilocybin, MDMA |
| Trifecta Research Study | NCT06810765 | Withdrawn | Phase 2 | 2025-09-01 | DMT, 5-MeO-DMT, Ibogaine |
| Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | NCT07737054 | Recruiting | Early Phase 1 | 2025-07-22 | Psilocybin |
| Ketamine, SGB and Combination Treatment for TBI | NCT06608277 | Recruiting | Phase 2 | 2025-07-02 | Ketamine |
| MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents | NCT06353282 | Withdrawn | Phase 2 | 2025-07-01 | MDMA |
| Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder) | NCT06795659 | Completed | Phase 1 | 2025-06-09 | Ketamine |
| Dose Optimization of MDMA-Assisted Therapy for PTSD | NCT06418178 | Recruiting | Phase 2 | 2025-06-03 | MDMA |
| Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | NCT06853912 | Active, not recruiting | Phase 2 | 2025-06-01 | Psilocybin |
| High-Intensity Inpatient MDMA-Assisted Psychotherapy for PTSD | NCT06954025 | Enrolling by invitation | Phase 2 | 2025-05-16 | MDMA |
| Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions | NCT06823024 | Enrolling by invitation | Not reported | 2025-02-18 | Ketamine |
| MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder | NCT05837845 | Recruiting | Phase 2 | 2025-02-10 | MDMA |
| State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma | NCT06888128 | Recruiting | Phase 2 | 2025-01-30 | Psilocybin |
| Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder | NCT05562973 | Withdrawn | Phase 1 | 2025-01-01 | Psilocybin |
| MDMA-Assisted CBCT for PTSD vs CBCT RCT | NCT06044675 | Recruiting | Phase 2 | 2024-11-15 | MDMA |
| MDMA-assisted Massed Prolonged Exposure for PTSD | NCT06117306 | Active, not recruiting | Phase 3 | 2024-10-25 | MDMA |
| Open-Label Psilocybin Study in Transdiagnostic Population | NCT06442423 | Recruiting | Phase 1 | 2024-10-17 | Psilocybin |
| The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD | NCT06414356 | Recruiting | Phase 4 | 2024-10-02 | Ketamine |
| A Study of Psilocybin for PTSD | NCT06407635 | Active, not recruiting | Phase 1 | 2024-06-07 | Psilocybin |
| The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD. | NCT03752918 | Withdrawn | Phase 1 | 2024-05-01 | MDMA |
| MDMA for Co-occurring PTSD and OUD After Childbirth | NCT05219175 | Recruiting | Phase 2 | 2024-04-16 | MDMA, LSD |
| Ketamine Treatment for PTSD and MDD in TBI | NCT06228391 | Not yet recruiting | Phase 2 | 2024-03-01 | Ketamine |
| Examining 3,4-methylenedioxymethamphetamine (MDMA) Effects on Psychological, Relational and Hyperarousal-Related Neural Reactivity Mechanisms in Veterans With PTSD and Moral Injury | NCT06394284 | Recruiting | Phase 3 | 2024-02-18 | MDMA |
| MDMA Plus Exposure Therapy for PTSD | NCT05746572 | Enrolling by invitation | Phase 2 | 2024-02-13 | MDMA |
| MDMA for AUD/PTSD Comorbidity | NCT05943665 | Completed | Phase 2 | 2024-02-06 | MDMA |
| Connectivity Changes Associated With Ketamine Assisted Psychotherapy for PTSD | NCT06036511 | Withdrawn | Phase 1 | 2023-12-31 | Ketamine |
| Evaluation of Psilocybin-Assisted Psychotherapy in Treating Severe Depression in Patients With PTSD | NCT06141876 | Status not reported | Phase 2 | 2023-12-15 | Psilocybin |
| MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD | NCT05979844 | Completed | Phase 3 | 2023-10-06 | MDMA |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk